Masks and accessories were the standout growth category for Resmed in the second quarter of its fiscal year 2026, with the company reporting a 16% increase in revenue in the United States, Canada and ...

Resmed has beaten expectations with $2 billion in second-quarter revenue and says weight loss drugs are actually boosting sales, rather than hurting them.

Resmed has beaten expectations with $2 billion in second-quarter revenue and says weight loss drugs are actually boosting ...

Q2 FY2026 earnings call recap: 11% revenue growth, margin expansion, AI innovation, and updated 62–63% guidance—read key takeaways now.

Medical device maker ResMed on Thursday beat Wall Street estimates for second-quarter profit on the back of strong demand for ...

Revenue increased by 11% to $1.4 billion; up 9% on a constant currency basis Gross margin up 320 bps to 61.8%; non-GAAP gross margin up 310 bps ...

Sleep apnea is a serious condition, causing breathing to stop and start several times during sleep. The most common form of the condition is obstructive sleep apnea, where the throat narrows, blocking ...

Amid trashed valuations, investors await for signs of life for healthcare stocks in the February profit-reporting season.

Tirzepatide use is associated with a lower risk for CPAP use, hospitalization, and mortality in adults with obesity, T2D, and OSA.

Canaday was named chief of staff for the executive team at Resmed in January 2022. Later that year, she moved into the ...

SAN DIEGO – Resmed has received clearance from the U.S. Food and Drug Administration (FDA) for an artificial intelligence (AI)-enabled device that recommends personalized comfort settings to help ...